1
Selected Clinical Trials in Supportive Cancer Therapy Trial Sponsor Contact Information rombocytopenia Prevention A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide A Phase II Study of Obatoclax Mesylate (GX15-070MS) in Patients with Previously- Untreated Myelodysplastic Syndromes (MDS) with Anemia and/or rombocytopenia Hot Flashes Phase III Randomized, Double-Blind, Placebo-Controlled Evaluation of Citalopram for the Treatment of Hot Flashes Emesis A Phase II/III Randomized, Controlled Clinical Trial of Ginger (Zingiber Officinale) for Nausea Caused by Chemotherapy for Cancer Effects of Acupoint Electro-Stimulation on Preventing Nausea and Vomiting Induced by Cisplatin or Oxaliplatin Neuropathy Prevention e Use of Vitamin E for Prevention of Chemotherapy-Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo-Controlled Study Prevention of Cisplatin- or Oxaliplatin-Induced Peripheral Neuropathy with Alpha-Lipoic Acid: A Placebo-Controlled Phase III Trials Bone Loss/Pain Management A Randomized, Double-Blinded Study of Actonel for the Prevention of Bone Loss in Patients Receiving High-Dose Corticosteroids for the Treatment of Acute Lymphocytic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) Rash A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Prophylactic Topical Sunscreen to Prevent Erlotinib- or Cetuximab-Induced Skin Rash (or Other Epidermal Growth Factor Receptor [EGFR] Inhibitor–Induced Skin Rash) Mucositis A Randomized, Phase III, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Palifermin (NSC# 740548; IND # 6370) for the Reduction of Oral Mucositis in Patients with Locally Advanced Head and Neck Cancer Receiving Radiation erapy with Concurrent Chemotherapy (Followed by Surgery for Selected Patients) Amgen Gemin X North Central Cancer Treatment Group (NCCTG); National Cancer Institute (NCI) University of Rochester; NCI M. D. Anderson Cancer Center (MDACC); NCI NCCTG; NCI MDACC; NCI MDACC; Procter and Gamble Pharmaceuticals NCCTG; NCI Radiation erapy Oncology Group; NCI ClinicalTrials.gov Identifier NCT00418665 NCT00413114 NCT00363909 NCT00040742 NCT00430313 NCT00363129 NCT00112996 NCT00452439 NCT00362986 NCT00360971 Amgen Call Center 866-572-6436 Tara Porrey 610-640-5735 Ext. 23 [email protected] Danielle Stabulis 610-640-5735 Ext. 35 [email protected] Debra Barton, RN, PhD, Study chair/Principal investigator 507-538-7623 [email protected] Beth La Vasseur, RN, MS, Study chair/Principal investigator 734-712-5658; 888-474-4673 [email protected] Jane T. Hickok, MD, MPH Study chair 585-275-5513 Joseph S. Chiang, MD 713-794-5363 Lisa Kottschade RN, MSN, CNP Study chair/Principal investigator 507-538-7623 [email protected] Ying Guo, MD, MS Principal investigator 713-745-2327 [email protected] Maria E. Cabanillas, MD Principal investigator 713-745-0654 Aminah Jatoi, MD Study chair 507-284-2511 Abby R. rower, MD, PhD Study co-chair 319-363-8303 David Rosenthal, MD Study chair 713-563-2300; 800-392-1611 clinical trials Supportive Cancer Therapy 168 Electronic forwarding or copying is a violation of US and International Copyright Laws. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1543-2912, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.
